Report Analysis and Forecast on Asthma - Pipeline Review, H2 2016

Asthma - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Complete report available @ Asthma - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 16, 44, 36, 124, 25 and 2 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 24 and 8 molecules, respectively for Asthma.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Asthma - Companies Involved in Therapeutics Development 4D Pharma Plc AB Science SA AbbVie Inc Abeome Corporation Accolade Pharmaceuticals, LLC Acorda Therapeutics, Inc. Adamis Pharmaceuticals Corporation Advinus Therapeutics Ltd Afferent Pharmaceuticals, Inc. ALK-Abello A/S Allergopharma GmbH & Co. KG Almirall, S.A. Amakem NV Amgen Inc. AnaptysBio, Inc. AnGes MG, Inc. Antisense Therapeutics Limited ARA Healthcare Pvt. Ltd. Array BioPharma Inc. ASIT biotech s.a. Astellas Pharma Inc. AstraZeneca Plc Asubio Pharma Co., Ltd. Aurigene Discovery Technologies Limited Axikin Pharmaceuticals, Inc. Bioncotech Therapeutics SL Biotec Pharmacon ASA Boehringer Ingelheim GmbH CalciMedica, Inc. Cellceutix Corporation Cellular Biomedicine Group, Inc. Celon Pharma Sp. z o.o. Chiesi Farmaceutici SpA Circassia Pharmaceuticals Plc Cognosci, Inc. CSL Limited Cumberland Pharmaceuticals, Inc. etc,.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###